Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...
Biohaven Ltd.: Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...
Le Lézard6d
Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S?1117, a Novel Pan?IgG Protease Therapy for Antibody-Mediated Diseases
Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of S?1117, a novel engineered Fc-fused ...
Fierce Biotech15h
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug ...
Morningstar14d
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...
Biohaven reports ‘positive’ data from study of BHV-1300
Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...
GlobalData on MSN5d
Seismic Therapeutic doses first healthy participant cohort in Phase I trial of S-1117
US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...
Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...
Scientists reveal key mechanism behind heavy-ion cancer therapy
The findings, led by researchers from the Institute of Modern Physics (IMP) of the Chinese Academy of Sciences and their ...
Neuroscience News6d
How a Common Virus Triggers Brain Attacks in Multiple Sclerosis
New research highlights a critical link between antibodies produced against Epstein-Barr virus (EBV) and the development of ...